Related references
Note: Only part of the references are listed.Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
J. C. Soria et al.
ANNALS OF ONCOLOGY (2010)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
Everardo D. Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
Christopher G. Azzoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
Katsuyuki Hotta et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
Kent R. Johnson et al.
LANCET ONCOLOGY (2006)
Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
HA Wakelee et al.
CANCER (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer
K Hotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results
OS Breathnach et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
FV Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
AB Sandler et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
